Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) | RFA CA 21 008

Opportunity Information: Apply for RFA CA 21 008

This grant opportunity, titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)," is a National Institutes of Health (NIH) funding announcement from the National Cancer Institute (NCI) designed specifically for teams that already hold an active NCI U01 cooperative agreement. Rather than funding entirely new projects, it supports revision applications (formerly called competing revisions) that add a significant, well-justified expansion to the parent U01 study. The central idea is to speed up progress on the existing research aims by integrating a new technology or technical approach that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program.

The core purpose of the announcement is twofold. First, it encourages investigators to broaden or deepen the scientific questions of an ongoing NCI U01 project by adding an IMAT-derived tool, platform, instrument, or method that can materially improve what the parent study can accomplish. Second, it aims to incentivize independent validation of emerging IMAT technologies in real-world research settings. In practice, that means the supplement-like revision is expected to help demonstrate whether a newer technology is reliable, suitable, and ready to be adopted by the wider cancer research community, rather than remaining limited to the original technology developer's lab.

This FOA sits within the broader IMAT program mission, which emphasizes interdisciplinary collaboration and the creation of novel molecular and analytical tools that can unlock new capabilities in cancer research. By encouraging NCI U01 awardees to bring IMAT innovations into active, externally funded projects, NCI is trying to shorten the time between technology development and meaningful scientific impact. The "Clinical Trial Optional" label signals that the proposed revision work may involve a clinical trial if appropriate, but a clinical trial is not required for eligibility under the announcement.

From an administrative and funding standpoint, the mechanism is a cooperative agreement (U01). That matters because, compared with standard research project grants, cooperative agreements typically involve substantial scientific or programmatic involvement from NIH staff, reflecting a more collaborative relationship between the funded investigators and NCI. The opportunity is categorized as discretionary funding and aligned with the Education and Health activity category, with CFDA number 93.394. The published award ceiling is $150,000, indicating the maximum amount available per award under this revision FOA. The source data lists "ExpectedAwards:" without a number, suggesting the total number of awards was not specified in the provided excerpt. The opportunity was created on 2020-11-24, with an original closing date of 2021-09-29, so it was time-bound and aimed at active awards during that period.

Eligibility is broad in terms of institution types, but the key constraint is that applicants must already have a currently funded NCI U01 research project that can serve as the parent award. Within that framework, eligible applicant organizations include many common NIH-eligible entities such as public and private institutions of higher education, nonprofits (including both 501(c)(3) and non-501(c)(3) organizations), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district), as well as independent school districts and public housing authorities/Indian housing authorities. It also explicitly includes Native American tribal governments (federally recognized) and Native American tribal organizations (other than federally recognized tribal governments). In addition, the FOA highlights other eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, non-U.S. (foreign) entities, Indian/Native American tribal governments that are not federally recognized, and U.S. territories or possessions. The breadth of eligible organizations reflects an intent to support technology validation and adoption across diverse institutional settings and research communities.

In terms of what an applicant is expected to propose, the revision should not be a minor add-on or routine budget increase. It should be positioned as a meaningful acceleration or expansion of the parent U01's scientific trajectory through incorporation of an IMAT-supported technology. That could include using a new molecular assay, analytical platform, or instrument to answer the parent study's questions more efficiently, with higher resolution, or in a way that was previously infeasible. It could also involve extending the parent project into new sample types, new measurement capabilities, or new validation steps made possible by the IMAT tool. Importantly, the FOA frames the revisions as a way to independently test and validate emerging technologies, which implies careful attention to performance evaluation, reproducibility, suitability for the intended research context, and evidence that the technology can be used by groups beyond the original developers.

Overall, this opportunity is best understood as an NCI strategy to bridge the gap between technology innovation and widespread research use. By funding competitive revisions to existing U01 projects, NCI leverages active, well-structured cancer research studies as testbeds for IMAT-supported technologies, helping confirm that the tools work as promised and accelerating their readiness for broader adoption in cancer research.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2020-11-24.
• Applicants must submit their applications by 2021-09-29. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $150,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 21 008

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: